<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">18827606</PMID>
<DateCompleted>
<Year>2009</Year>
<Month>01</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1556-1380</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>3</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2008</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title>
<ISOAbbreviation>J Thorac Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1112-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/JTO.0b013e3181874936</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A trial of neoadjuvant gemcitabine and pemetrexed (GP) chemotherapy in patients with resectable non-small cell lung cancer was conducted. The goal was to achieve a disease response rate of 50% and to determine if the expression levels of genes associated with GP metabolism are predictive of response.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Patients had staging with a computed tomography scan, whole body F-18 fluorodeoxyglucose positron emission tomography, and mediastinoscopy. Four biweekly cycles of GP were given. Patients were restaged, and those with resectable stage IB-III disease had thoracotomy. Fresh frozen tumor specimens were collected before and after chemotherapy and the mRNA levels of 14 target genes determined by real-time reverse transcription polymerase chain reaction.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-two patients started therapy. The radiographic disease response rate was 35% (95% confidence interval 21.7-49.6%), and the progression rate was 6%. Forty-six patients had a thoracotomy. The complete tumor resection rate was 77% (40/52). There were no perioperative deaths or deaths related to chemotherapy. Tumor response to chemotherapy was inversely correlated with the level of expression of RRM1 (p &lt; 0.001; regulatory subunit of ribonucleotide reductase) and TS (p = 0.006; thymidylate synthase); i.e., the reduction in tumor size was greater in those with low levels of expression.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neoadjuvant GP is well tolerated and produces an objective response rate of 35%. Tumoral RRM1 and TS mRNA levels are predictive of disease response and should be considered as parameters for treatment selection in future trials with this regimen.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bepler</LastName>
<ForeName>Gerold</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Program and Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA. gerold.bepler@moffitt.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sommers</LastName>
<ForeName>K Eric</ForeName>
<Initials>KE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cantor</LastName>
<ForeName>Alan</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xueli</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sharma</LastName>
<ForeName>Anupama</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Williams</LastName>
<ForeName>Charles</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chiappori</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haura</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Antonia</LastName>
<ForeName>Scott</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanvetyanon</LastName>
<ForeName>Tawee</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Simon</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Obasaju</LastName>
<ForeName>Coleman</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robinson</LastName>
<ForeName>Lary A</ForeName>
<Initials>LA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R21 CA110487</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA110487-01A1</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K24 CA128953</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA110487-02</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA140314</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Thorac Oncol</MedlineTA>
<NlmUniqueID>101274235</NlmUniqueID>
<ISSNLinking>1556-0864</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005971">Glutamates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012334">RNA, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>04Q9AIZ7NO</RegistryNumber>
<NameOfSubstance UI="D000068437">Pemetrexed</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0W860991D6</RegistryNumber>
<NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5Z93L87A1R</RegistryNumber>
<NameOfSubstance UI="D006147">Guanine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>B76N6SBZ8R</RegistryNumber>
<NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005971">Glutamates</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006147">Guanine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020360">Neoadjuvant Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068437">Pemetrexed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012334">RNA, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2009</Year>
<Month>1</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18827606</ArticleId>
<ArticleId IdType="doi">10.1097/JTO.0b013e3181874936</ArticleId>
<ArticleId IdType="pii">S1556-0864(15)32083-9</ArticleId>
<ArticleId IdType="pmc">PMC2639211</ArticleId>
<ArticleId IdType="mid">NIHMS84692</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Clin Oncol. 2002 Jan 1;20(1):247-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11773176</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Thorac Oncol. 2008 Apr;3(4):394-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18379358</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2004 Jan 22;350(4):351-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14736927</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 May 15;22(10):1878-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15143080</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 1994 Jan 20;330(3):153-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8043059</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 1994 May 4;86(9):673-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8158698</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1999 Aug 1;59(15):3671-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10446980</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Jun 23;352(25):2589-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15972865</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2005 Sep 1;23(25):5929-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16135464</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chest. 2005 Nov;128(5):3467-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16304301</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2006 Aug 7;95(3):289-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16868547</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2006 Sep;7(9):719-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16945766</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2006 Sep 7;355(10):983-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16957145</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2007 Jun 9;369(9577):1929-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17544497</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Oncol. 2002 Dec;29(6 Suppl 18):30-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12571808</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>